Log in

NASDAQ:TCDA - Tricida Stock Price, Forecast & News

$36.72
+0.36 (+0.99 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$35.54
Now: $36.72
$36.80
50-Day Range
$32.97
MA: $36.02
$38.62
52-Week Range
$21.28
Now: $36.72
$44.30
Volume96,517 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TCDA
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees76
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.


Tricida (NASDAQ:TCDA) Frequently Asked Questions

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.89). View Tricida's Earnings History.

When is Tricida's next earnings date?

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

What price target have analysts set for TCDA?

3 analysts have issued 12-month target prices for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they anticipate Tricida's stock price to reach $51.50 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price. View Analyst Price Targets for Tricida.

What is the consensus analysts' recommendation for Tricida?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

Has Tricida been receiving favorable news coverage?

Media headlines about TCDA stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tricida earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Tricida.

Are investors shorting Tricida?

Tricida saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,040,000 shares, a drop of 7.6% from the January 15th total of 4,370,000 shares. Based on an average daily trading volume, of 322,300 shares, the days-to-cover ratio is presently 12.5 days. Currently, 11.3% of the company's stock are sold short. View Tricida's Current Options Chain.

What other stocks do shareholders of Tricida own?

Who are Tricida's key executives?

Tricida's management team includes the folowing people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
  • Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
  • Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
  • Steffen Pietzke, VP of Fin. & Chief Accounting Officer
  • Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Who are Tricida's major shareholders?

Tricida's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (2.02%), State Street Corp (1.02%), Driehaus Capital Management LLC (0.53%), Candriam Luxembourg S.C.A. (0.37%), Charles Schwab Investment Management Inc. (0.31%) and Point72 Asset Management L.P. (0.30%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

Which major investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Alpine Woods Capital Investors LLC, New York State Common Retirement Fund, ProShare Advisors LLC and Victory Capital Management Inc.. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

Which major investors are buying Tricida stock?

TCDA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cubist Systematic Strategies LLC, Credit Suisse AG, Renaissance Technologies LLC, Barclays PLC and AQR Capital Management LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $36.72.


MarketBeat Community Rating for Tricida (NASDAQ TCDA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel